(Reuters) - Shares in the Seattle-based group plunged 65 percent to $6.20 in electronic trading ahead of the Nasdaq open.
The drop comes just over a month after the stock more than doubled in a single session when a U.S. Food and Drug Administration advisory panel recommended approval.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment